Evidence map›Paper›PMID 41951841›Full record

ArticleBone marrow transplantation2026

Immune reconstitution in patients with myelofibrosis conditioned with a non-myeloablative regimen prior to allogeneic stem cell transplantation.

Morten Orebo Holmström, Lia Minculescu, Katrine Nørgaard, Hans Jakob Hartling, Brian Thomas Kornblit, Marietta Nygaard, Ida Schjødt, Mads Hald Andersen, Niels Smedegaard Andersen, Henrik Sengeløv and 4 more

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Morten Orebo HolmströmNational Center for Cancer Immune Therapy, Department of Oncology, Herlev-Gentofte Hospital, Herlev, Denmark. morten.orebo.holmstroem@regionh.dk.ORCID http://orcid.org/0000-0002-3764-8578
Lia MinculescuDepartment of Clinical Immunology, Rigshospitalet, Copenhagen, Denmark.
Katrine NørgaardDepartment of Clinical Genetics, Rigshospitalet, Copenhagen, Denmark.
Hans Jakob HartlingDepartment of Clinical Immunology, Rigshospitalet, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-4886-0419
Brian Thomas KornblitDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark.
Marietta NygaardDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-8339-8899
Ida SchjødtDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark.
Mads Hald AndersenNational Center for Cancer Immune Therapy, Department of Oncology, Herlev-Gentofte Hospital, Herlev, Denmark.ORCID http://orcid.org/0000-0002-2914-9605
Niels Smedegaard AndersenDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark.
Henrik SengeløvDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark.
Anne Werner HaugeDepartment of Clinical Immunology, Rigshospitalet, Copenhagen, Denmark.
Søren Lykke PetersenDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark.
Mette Klarskov AndersenDepartment of Clinical Genetics, Rigshospitalet, Copenhagen, Denmark.
Lone Smidstrup FriisDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark.

Funding

Novo Nordisk Fonden (Novo Nordisk Foundation) NNF20SA0064340
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.